PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy AUTOLOGOUS CELLULAR IMMUNOTHERAPYPROVENGE is classified by the FDA as an autologous cellular immunotherapy. It is designed to be an active cellular immunotherapy. Closeto receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer.
For more information about PROVENGE, please visit www.PROVENGE.com.
US Health Care Professionals can visit the Medical Affairs Web site to submit a request online.